COVID-19 vaccine effectiveness against severe disease from SARS-CoV-2 Omicron BA.1 and BA.2 subvariants – surveillance results from southern Sweden, December 2021 to March 2022

We compared vaccine effectiveness against severe COVID-19 between December 2021 and March 2022 when Omicron BA.1 and BA.2 were the dominating SARS-CoV-2 variants in Scania county, Sweden. Effectiveness remained above 80% after the transition from BA.1 to BA.2 among people with at least three vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Björk, Jonas, Bonander, Carl, Moghaddassi, Mahnaz, Rasmussen, Magnus, Malmqvist, Ulf, Inghammar, Malin, Kahn, Fredrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2022
Materias:
Rapid Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074397/
https://www.ncbi.nlm.nih.gov/pubmed/35514304
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.18.2200322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9074397/
https://www.ncbi.nlm.nih.gov/pubmed/35514304
http://dx.doi.org/10.2807/1560-7917.ES.2022.27.18.2200322

Ejemplares similares